Patrick Moriarty
Dr. Moriarty is a Professor in the Department of Internal Medicine at the University of Kansas Medical Center in Kansas City and the Director of the Division of Clinical Pharmacology.
Dr. Moriarty is a Professor in the Department of Internal Medicine at the University of Kansas Medical Center in Kansas City and the Director of the Division of Clinical Pharmacology. He is also the Medical Director of the Atherosclerosis and Lipoprotein-Apheresis Clinic.

After completing his undergraduate education in the United States, Dr. Moriarty attended the Universita Di Roma where he earned his doctor of medicine and surgery degree. He completed his residency at the University of Kansas Medical Center and also completed a fellowship in clinical pharmacology there. He subsequently joined the faculty and earned academic promotions over an academic career of more than 20 years.

An active researcher for the pharmaceutical industry, Dr. Moriarty has acted as principal investigator or co-investigator for numerous studies on treatments for hypercholesterolemia, therapeutic apheresis, and lipid-altering strategies in patients with diabetes. Currently, he is serving as the National Medical Monitor for the EFC 11570 Odyssey Outcomes study. His research has generated a long list of peer-reviewed articles and abstracts and has been the basis for lectures around the world. Dr. Moriarty has been a featured presenter at congresses of the World Apheresis Association, the International Society for Apheresis, the American Society for Apheresis, and the National Lipid Association, among other organizations.

Dr. Moriarty is Associate editor for the Journal of Clinical Apheresis and for Future Lipidology. He recently co-authored a chapter on familial hypercholesterolemia for the 2015 second edition of Clinical Lipidology: A Companion to Braunwald’s Heart Disease.

Involved with various medical societies, Dr. Moriarty serves on the Board of Directors for the Midwest Lipid Association and the International Society for Atherosclerosis, and on the Medical Advisory Board for the FH Foundation and the Lp(a) Foundation. He is president of the International Society for Apheresis. He belongs to the European Atherosclerosis Society, the Society of Atherosclerosis Imaging, and the American Society of Clinical Pharmacological Therapeutics. He is a fellow of the National Lipid Association, American Society of Physicians, and the American College of Cardiology.

Dr. Moriarty was named in Who’s Who in Diabetes Treatment, Education, and Research for 2008. He received the 2001 Student Voice Excellence in Teaching Award from the University of Kansas Medical Center.
 
FOUNDING PARTNERS:






Lipid and Blood Pressure
Meta-analysis Collaboration Group
Zeromskiego 113
90-549 Lodz, Poland
Phone/Fax: +48 42 639 37 71
Email: maciej.banach@umed.lodz.pl
© 2018 LBPMC. All rights reserved.